Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ATOS Stock Forecast 2026-2027
$5.77
Current Price
$49.69M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ATOS Price Targets
+333.3%
To High Target of $25.00
+315.9%
To Median Target of $24.00
+246.6%
To Low Target of $20.00
ATOS Price Momentum
+0.5%
1 Week Change
+8.3%
1 Month Change
-41.7%
1 Year Change
-34.8%
Year-to-Date Change
-70.2%
From 52W High of $19.35
+53.5%
From 52W Low of $3.76
📊 TOP ANALYST CALLS
Did ATOS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Atossa is one of their latest high-conviction picks.
Latest ATOS Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ATOS has a bullish consensus with a median price target of $24.00 (ranging from $20.00 to $25.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $5.77, the median forecast implies a 315.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 333.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATOS Analyst Ratings
3
Buy
0
Hold
0
Sell
ATOS Price Target Range
Low
$20.00
Average
$24.00
High
$25.00
Current: $5.77
Latest ATOS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATOS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Ascendiant Capital | Edward Woo | Buy | Maintains | $24.00 |
| Mar 26, 2026 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $25.00 |
| Dec 8, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.00 |
| Sep 22, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.75 |
| Jun 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.50 |
| Jun 5, 2025 | Craig-Hallum | Albert Lowe | Buy | Initiates | $4.00 |
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.25 |
| Mar 26, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Dec 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $7.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $N/A |
| Dec 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $7.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Sep 11, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $6.50 |
| Aug 12, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $6.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
Atossa Therapeutics Inc. (ATOS) Competitors
The following stocks are similar to Atossa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ATOS
Atossa Genetics
mkt cap
50.20M
Atossa Therapeutics Inc. (ATOS) Financial Data
Atossa Therapeutics Inc. has a market capitalization of $49.69M with a P/E ratio of -1.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -62.7%.
Valuation Metrics
Market Cap
$49.69M
Enterprise Value
$8.39M
P/E Ratio
-1.4x
PEG Ratio
-2.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+83.1%
Current Ratio
5.5x
Debt/Equity
0.0x
ROE
-62.7%
ROA
-37.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Atossa Therapeutics Inc. (ATOS) Business Model
About Atossa Therapeutics Inc.
What They Do
Develops investigational oncology medicines.
Business Model
Atossa Therapeutics operates as a clinical-stage biopharmaceutical company focusing on the development of its proprietary drug, (Z)-Endoxifen, for breast cancer treatment and prevention. The company generates value by advancing its clinical trials and exploring various applications for its drug, including potential uses in other hormone-driven conditions and rare diseases, while building a strong intellectual property portfolio to support regulatory approvals.
Additional Information
Founded in 2009 and based in Seattle, Washington, Atossa Therapeutics currently has no approved products and aims to concentrate its resources on research, clinical execution, and regulatory strategies in women's oncology, particularly targeting unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Country
United States
IPO Year
2012
Website
www.atossatherapeutics.comAtossa Therapeutics Inc. (ATOS) Latest News & Analysis
Latest News
Quick Summary
Atossa Therapeutics (Nasdaq: ATOS) reported its Q4 and full-year 2025 financial results, highlighting progress in its (Z)-endoxifen oncology development and plans to address unmet medical needs.
Why It Matters
Atossa's progress in oncology and exploration of new opportunities may enhance its market position and drive future growth, impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Dr. Kathy Puyana Theall and Dr. Adebola Giwa have been mentioned in a news excerpt, but no specific details or context about their relevance to investors are provided.
Why It Matters
The mention of specific doctors suggests potential developments in healthcare, possibly indicating new treatments or research that could influence stock prices in the health sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atossa Therapeutics presented positive findings on (Z)-endoxifen at a conference, showing it improves muscle performance and reduces damage in dystrophic mice, with no adverse effects noted.
Why It Matters
Atossa Therapeutics' positive findings on (Z)-endoxifen in a mouse model for Duchenne muscular dystrophy suggest potential for a breakthrough treatment, enhancing investor confidence in its future market value.
Source: PRNewsWire
Market Sentiment:
Neutral
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
2 months ago
Quick Summary
Atossa Therapeutics (Nasdaq: ATOS) provided a shareholder update on its clinical programs and recent developments in a letter from CEO Steven Quay, as of February 11, 2026.
Why It Matters
Atossa Therapeutics' update on clinical programs can influence stock performance, affecting investor sentiment and potential future valuations based on developmental progress.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atossa Therapeutics received Rare Pediatric Disease designation for (Z)-endoxifen in DMD, enabling eligibility for a Priority Review Voucher upon FDA approval, following a recent program reauthorization.
Why It Matters
Atossa's Rare Pediatric Disease designation for (Z)-endoxifen enhances its market prospects and potential revenue through a PRV, signaling a significant opportunity in the DMD treatment space.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Atossa Therapeutics' CEO, Dr. Steven Quay, was named one of the "Top 50 Healthcare Technology CEOs of 2025" by The Healthcare Technology Report, highlighting his leadership in oncology innovations.
Why It Matters
Steven Quay's recognition enhances Atossa's reputation and could boost investor confidence, potentially leading to increased stock value and interest in its innovative therapies.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ATOS Stock
What is Atossa Therapeutics Inc.'s (ATOS) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Atossa Therapeutics Inc. (ATOS) has a median price target of $24.00. The highest price target is $25.00 and the lowest is $20.00.
Is ATOS stock a good investment in 2026?
According to current analyst ratings, ATOS has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATOS stock?
Wall Street analysts predict ATOS stock could reach $24.00 in the next 12 months. This represents a 315.9% increase from the current price of $5.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Atossa Therapeutics Inc.'s business model?
Atossa Therapeutics operates as a clinical-stage biopharmaceutical company focusing on the development of its proprietary drug, (Z)-Endoxifen, for breast cancer treatment and prevention. The company generates value by advancing its clinical trials and exploring various applications for its drug, including potential uses in other hormone-driven conditions and rare diseases, while building a strong intellectual property portfolio to support regulatory approvals.
What is the highest forecasted price for ATOS Atossa Therapeutics Inc.?
The highest price target for ATOS is $25.00 from Emily Bodnar at HC Wainwright & Co., which represents a 333.3% increase from the current price of $5.77.
What is the lowest forecasted price for ATOS Atossa Therapeutics Inc.?
The lowest price target for ATOS is $20.00 from at , which represents a 246.6% increase from the current price of $5.77.
What is the overall ATOS consensus from analysts for Atossa Therapeutics Inc.?
The overall analyst consensus for ATOS is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $24.00.
How accurate are ATOS stock price projections?
Stock price projections, including those for Atossa Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 4:59 AM UTC